# Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

> **NCT01267812** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **DRUG:** bortezomib
- **BIOLOGICAL:** rituximab
- **OTHER:** laboratory biomarker analysis
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** RNA analysis
- **GENETIC:** gene expression analysis
- **GENETIC:** DNA analysis
- **OTHER:** pharmacological study
- **OTHER:** pharmacogenomic studies
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT01267812
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-03
- **Primary completion:** 2020-11-02
- **Final completion:** 2020-11-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01267812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01267812, "Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01267812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*